NZ509595A - Peg-urate oxidase conjugates and use thereof - Google Patents

Peg-urate oxidase conjugates and use thereof

Info

Publication number
NZ509595A
NZ509595A NZ509595A NZ50959599A NZ509595A NZ 509595 A NZ509595 A NZ 509595A NZ 509595 A NZ509595 A NZ 509595A NZ 50959599 A NZ50959599 A NZ 50959599A NZ 509595 A NZ509595 A NZ 509595A
Authority
NZ
New Zealand
Prior art keywords
peg
uricase
urate oxidase
kda
poly
Prior art date
Application number
NZ509595A
Other languages
English (en)
Inventor
L David Williams
Michael S Hershfield
Susanj Kelly
Mark G P Saifer
Merry R Sherman
Original Assignee
Univ Duke
Mountain View Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Mountain View Pharmaceuticals filed Critical Univ Duke
Publication of NZ509595A publication Critical patent/NZ509595A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ509595A 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof NZ509595A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13039298A 1998-08-06 1998-08-06
PCT/US1999/017514 WO2000007629A2 (en) 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof

Publications (1)

Publication Number Publication Date
NZ509595A true NZ509595A (en) 2004-02-27

Family

ID=22444494

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ509595A NZ509595A (en) 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof

Country Status (13)

Country Link
EP (1) EP1100542B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP5183836B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR100614212B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU770014B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BRPI9917760B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ303751B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU228916B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL141220A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ509595A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL202799B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (3) RU2246318C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW570981B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000007629A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1100880E (pt) 1998-08-06 2011-01-13 Univ Duke Urato-oxidase
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CN1896231B (zh) 1998-08-06 2012-09-05 山景药品公司 分离四聚体尿酸氧化酶的方法
WO2000007629A2 (en) * 1998-08-06 2000-02-17 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
AU2006203252B8 (en) * 2000-02-10 2009-06-18 Duke University Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP1279406A4 (en) 2000-04-03 2007-10-24 Santen Pharmaceutical Co Ltd TRANSPORTERS AND DRUG DISPENSING SYSTEMS USING THESE
CA2413201A1 (en) * 2000-06-28 2002-01-03 Merck & Co., Inc. Treatment for cardiovascular disease
DK1421175T3 (da) 2001-06-28 2009-03-23 Mountain View Pharmaceuticals Polymerstabiliserede proteinaser
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO2004100997A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Spacer moiety for poly(ethylene glycol) -modified peptides
KR101227666B1 (ko) 2003-05-12 2013-01-31 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 펩티드
EP1765411B2 (en) * 2004-06-30 2017-10-11 Nektar Therapeutics Polymer-factor ix moiety conjugates
MX2007012548A (es) 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP2947145A1 (en) 2005-04-11 2015-11-25 Crealta Pharmaceuticals LLC Variant forms of urate oxidase and use thereof
US8841333B2 (en) 2005-05-09 2014-09-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating nephrolithiasis
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
PL2013225T3 (pl) 2006-04-12 2015-06-30 Crealta Pharmaceuticals Llc Oczyszczanie białek z zastosowaniem kationowego środka powierzchniowo czynnego
JP4890132B2 (ja) * 2006-07-20 2012-03-07 東洋紡績株式会社 ウリカーゼの比活性を向上させる方法、および比活性の向上した改変型ウリカーゼ
RU2382048C1 (ru) * 2008-12-25 2010-02-20 Общество С Ограниченной Ответственностью "Фармапарк" Лекарственное средство на основе модифицированного интерферона альфа с пролонгированным терапевтическим действием
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
EP2613780B1 (en) 2010-09-10 2014-11-12 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
EP2833883A4 (en) 2012-04-06 2015-12-23 Indus Pharmaceuticals Inc NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES
MY190411A (en) 2015-05-15 2022-04-21 Medimmune Llc Improved uricase sequences and methods of treatment
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
JP7523909B2 (ja) 2017-03-11 2024-07-29 セレクタ バイオサイエンシーズ インコーポレーテッド 抗炎症剤および免疫抑制剤を含む合成ナノキャリアによる組み合わせ処置に関連する方法および組成物
CN112980808B (zh) * 2019-12-12 2024-10-29 深圳迈瑞生物医疗电子股份有限公司 尿酸酶、及其制备方法和用途
JP2023548496A (ja) 2020-11-03 2023-11-17 プロタリクス リミテッド 修飾ウリカーゼ及びその使用
CN114438047B (zh) * 2020-11-05 2024-11-22 重庆派金生物科技有限公司 制备聚乙二醇修饰的尿酸氧化酶的方法
CN114438048B (zh) * 2020-11-05 2024-10-22 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
JPWO2022172343A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-02-10 2022-08-18
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1529675A (fr) * 1967-03-29 1968-06-21 Applic Biochimiques Soc Et Urate oxydase à haute activité et sa préparation
US3616231A (en) * 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6031472B2 (ja) * 1978-12-14 1985-07-22 協和醗酵工業株式会社 酸性ウリカ−ゼ
JPS55135590A (en) * 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
JPS57192435A (en) * 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
WO2000007629A2 (en) * 1998-08-06 2000-02-17 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
PT1100880E (pt) * 1998-08-06 2011-01-13 Univ Duke Urato-oxidase

Also Published As

Publication number Publication date
KR20040088585A (ko) 2004-10-16
KR100488848B1 (ko) 2005-05-11
KR100614212B1 (ko) 2006-08-21
BRPI9912974B8 (pt) 2021-05-25
PL346224A1 (en) 2002-01-28
BRPI9917760B8 (pt) 2021-05-25
IL141220A (en) 2007-09-20
HUP0103003A2 (hu) 2001-11-28
BR9912974A (pt) 2001-05-08
RU2004104953A (ru) 2005-07-27
KR20010072287A (ko) 2001-07-31
AU770014B2 (en) 2004-02-12
EP1100542B1 (en) 2005-06-22
RU2278680C2 (ru) 2006-06-27
HU226294B1 (en) 2008-08-28
RU2349341C2 (ru) 2009-03-20
HUP0103003A3 (en) 2006-04-28
RU2246318C2 (ru) 2005-02-20
RU2006107111A (ru) 2007-09-20
EP1100542A2 (en) 2001-05-23
IL183948A0 (en) 2007-10-31
WO2000007629A2 (en) 2000-02-17
BRPI9912974B1 (pt) 2015-08-25
TW570981B (en) 2004-01-11
BR9917760B1 (pt) 2014-11-25
JP2009254376A (ja) 2009-11-05
JP2002522399A (ja) 2002-07-23
JP5183836B2 (ja) 2013-04-17
CZ2001317A3 (cs) 2001-07-11
PL202799B1 (pl) 2009-07-31
JP5290901B2 (ja) 2013-09-18
WO2000007629A3 (en) 2000-06-08
IL141220A0 (en) 2002-03-10
AU5251599A (en) 2000-02-28
IL183948A (en) 2010-11-30
HU228916B1 (en) 2013-06-28
PL383331A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2002-01-28
JP5291235B2 (ja) 2013-09-18
PL220873B1 (pl) 2016-01-29
JP2013039139A (ja) 2013-02-28
CZ303751B6 (cs) 2013-04-24

Similar Documents

Publication Publication Date Title
CY1119848T1 (el) Απομονωμενη τετραμερικη ουρικαση
NZ509595A (en) Peg-urate oxidase conjugates and use thereof
WO2002026265A3 (en) Pegylated interleukin-10
HK1054684A1 (zh) 包含高分子量聚环氧乙烷的多价平台分子
CA2323048A1 (en) Poly(ethylene glycol) derivatives with proximal reactive groups
AU7761594A (en) Polyethylene glycols
PL374318A1 (en) Pegylated factor vii glycoforms
WO1997025052A3 (en) Compositions comprising pvp having an average molecular weight in the range of 3,000 to 14,000 daltons
RS49533B (sr) Interferonski konjugati
WO2002040055A3 (en) Solutions and films of glycated chitosan
ES2343105T8 (es) Urato oxidasa sin agregados para la preparacion de conjugados poliméricos no inmunogénicos
MY131553A (en) Lyophilized formulation of polyethylene oxide modified proteins with increased self-life
AU2002335133A1 (en) Polyether ester elastomer comprising polytrimethylene ether ester soft segment and tetramethylene ester hard segment
WO2005058366A3 (en) Compositions comprising two different populations of polymer-active agent conjugates
PT1521600E (pt) Conjugados de bis-aciloxipropil-cisteína e sua utilização
EP0950708A3 (en) Enhanced affinity hyaluronan binding peptides
WO2005084303A3 (en) Interferon-beta polymer conjugates
CY1114005T1 (el) Συζευγματα peg-ουρικης οξειδασης και χρηση αυτων
WO2001081556A3 (en) Enzyme variants having one or more d-amino acid substitutions
EP1025860A3 (de) Proteinhaltige Hydrogele
CA2249215A1 (en) Modified pectin material
AU1228300A (en) Fabric care compositions having reduced fabric abrasion
CA2242618A1 (en) Compositions comprising ultrapure pvp having an average molecular weight in the range of 7,000 to 12,000 daltons

Legal Events

Date Code Title Description
PSEA Patent sealed
S35A Application for proceedings under section 35 (restoration of lapsed patents)
RENW Renewal (renewal fees accepted)
S35R Proceedings under section 35 (restoration of lapsed patents): patent restored
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired